Cue Biopharma, Inc. Insider Trading Activity
Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Warren holds 250,000 stock options directly.
Insider Trade Summary
Grant/Award: 250,000 shares
Grant/Award
1 txn
Insider
Warren Lucinda
Role
CHIEF BUSINESS OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 250,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 250,000 contracts (Direct)
Footnotes (1)
- F1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Key Figures
Stock options granted: 250,000 options
Exercise price: $0.29 per share
Underlying shares: 250,000 shares
+2 more
5 metrics
Stock options granted
250,000 options
Grant to Chief Business Officer on April 9, 2026
Exercise price
$0.29 per share
Strike price for granted stock options
Underlying shares
250,000 shares
Common stock underlying the options
Expiration date
April 8, 2036
Option term for the grant
Post-grant option holdings
250,000 options
Total stock options held directly after the grant
Key Terms
Stock Option (right to buy), exercise price, vesting, semi-annual installments, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "0.2900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
semi-annual installments financial
"the remainder vesting in equal, semi-annual installments thereafter"
expiration date financial
"expiration_date: "2036-04-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cue Biopharma (CUE) report for Lucinda Warren?
Cue Biopharma reported that Chief Business Officer Lucinda Warren received a grant of 250,000 stock options. These options give her the right to buy common shares at a fixed price, aligning part of her compensation with the company’s future share performance over time.
What is the exercise price of Lucinda Warren’s new stock options at Cue Biopharma (CUE)?
The stock options granted to Lucinda Warren have an exercise price of $0.29 per share. This means she can purchase Cue Biopharma common stock at $0.29 once the options vest, regardless of the market price at the time of exercise.
How do Lucinda Warren’s Cue Biopharma (CUE) stock options vest over time?
Lucinda Warren’s options vest over four years, with 25% becoming exercisable on the one-year anniversary of the grant date. The remaining 75% then vest in equal semi-annual installments, gradually increasing her exercisable option position during the vesting period.
When do Lucinda Warren’s Cue Biopharma (CUE) stock options expire?
The granted stock options expire on April 8, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Cue Biopharma common shares, setting a long-term window for potential exercise.
How many Cue Biopharma (CUE) stock options does Lucinda Warren hold after this grant?
Following this grant, Lucinda Warren holds 250,000 stock options directly. All of these options relate to Cue Biopharma common stock, with vesting conditions and a long-dated expiration that tie her potential upside to the company’s long-term performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates